Pharmaceutical

EC approves Otsuka and Lundbeck’s Rxulti for schizophrenia

The EC has approved Otsuka Pharmaceutical and Lundbeck’s atypical oral antipsychotic, Rxulti (brexpiprazole), for treating schizophrenia.

Mar 15, 2025 - 06:00
EC approves Otsuka and Lundbeck’s Rxulti for schizophrenia
The EC has approved Otsuka Pharmaceutical and Lundbeck’s atypical oral antipsychotic, Rxulti (brexpiprazole), for treating schizophrenia.
Read the original article

Tags:

Previous Article

MeiraGTx and Hologen launch AI-backed gene therapy venture

Next Article

Insilico raises $110m to develop drug pipeline and AI platform

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA seeks to regulate lab-developed tests, closing the ‘Theranos loophole’

STAT+: FDA seeks to regulate lab-developed tests, closi...

Sep 30, 2023

STAT+: FTC countersues HCA, Louisiana hospital system to stop acquisitions

STAT+: FTC countersues HCA, Louisiana hospital system t...

Apr 21, 2023

Amazon expands telehealth clinic nationwide

Amazon expands telehealth clinic nationwide

Aug 1, 2023